Literature DB >> 21692072

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease.

Ferial Shihadeh1, Valerie Reed, Stefan Faderl, L Jeffrey Medeiros, Ali Mazloom, Mersiha Hadziahmetovic, Hagop Kantarjian, Pamela Allen, Leslie Ballas, Sherry Pierce, Bouthaina Dabaja.   

Abstract

BACKGROUND: Acute myeloid leukemia (AML) infrequently involves the central nervous system (CNS). This study was undertaken in patients with AML to determine whether cytogenetic findings predict CNS involvement.
METHODS: The medical records of 1354 patients with AML who were treated at The University of Texas MD Anderson Cancer Center between January 2000 and December 2008 were reviewed. Forty patients (3%) had CNS involvement at time of presentation or disease recurrence, of whom 37 had conventional cytogenetics performed on bone marrow aspirate material. Demographics, treatment, and status at last follow-up were collected.
RESULTS: Eleven patients (30%) had a diploid karyotype, and 14 patients (38%) had complex cytogenetics. Only 5 of the 40 patients had CNS disease at diagnosis, and the remaining patients had CNS disease at relapse. Patients who developed CNS disease were younger (P = .019), had a higher white blood cell (WBC) count at diagnosis (P = .001), had higher lactate dehydrogenase level (LDH) levels (P < .0001), and had higher percentages peripheral blast cells (P = .024) at diagnosis compared with the rest of the population. In addition, patients with CNS disease had higher rates of chromosome 16 inversion (P < .001), chromosome 11 abnormality (P = .005), and trisomy 8 (P = .02) and had a tendency toward complex cytogenetics (P = .2) compared with the control group (patients who had AML with no CNS involvement).
CONCLUSIONS: Patients with AML and CNS disease often had higher LDH levels and WBC counts at diagnosis, and they often presented with chromosome 16 inversion and chromosome 11 abnormalities. The current study indicated that the overall survival of patients with AML who had CNS involvement is poor.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21692072     DOI: 10.1002/cncr.26253

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia.

Authors:  Ji Hyun Kwon; Young-Il Koh; Sung-Soo Yoon; Seonyang Park; Inho Kim
Journal:  Int J Hematol       Date:  2016-07-18       Impact factor: 2.490

2.  Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors:  Qi Chen; Xiao-Lu Zhu; Xin Zhao; Xiao Liu; Hai-Xia Fu; Yuan-Yuan Zhang; Yu-Hong Chen; Xiao-Dong Mo; Wei Han; Huan Chen; Chen-Hua Yan; Yu Wang; Ying-Jun Chang; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Ann Hematol       Date:  2021-01-02       Impact factor: 3.673

3.  Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.

Authors:  Uri Rozovski; Maro Ohanian; Farhad Ravandi; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Jorge Cortes; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2014-11-03

4.  Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.

Authors:  Elias Jabbour; Naval Guastad Daver; Nicholas James Short; Xuelin Huang; Hsiang-Chun Chen; Abhishek Maiti; Farhad Ravandi; Jorge Cortes; Simon Abi Aad; Guillermo Garcia-Manero; Zeev Estrov; Tapan Kadia; Susan O'Brien; Bouthaina Dabaja; Carlos Bueso-Ramos; Paolo Strati; Carol Bivins; Sherry Pierce; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

Review 5.  Neurological Complications of the Leukemias Across the Ages.

Authors:  Stephanie Berg; Sucha Nand
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

6.  Acute myeloid leukemia presenting with complete paraplegia and bilateral total blindness due to central nervous system involvement.

Authors:  Kohta Asano; Hidetaka Wakabayashi; Naohisa Kikuchi; Hironobu Sashika
Journal:  Spinal Cord Ser Cases       Date:  2016-04-07

7.  Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.

Authors:  Merav Bar; Weigang Tong; Megan Othus; Keith R Loeb; Elihu H Estey
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-26       Impact factor: 5.742

8.  Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.

Authors:  Donna L Johnston; Todd A Alonzo; Robert B Gerbing; Richard Aplenc; William G Woods; Soheil Meshinchi; Alan S Gamis
Journal:  Pediatr Blood Cancer       Date:  2017-04-28       Impact factor: 3.167

9.  Comprehensive craniospinal radiation for controlling central nervous system leukemia.

Authors:  Gary V Walker; Ferial Shihadeh; Hagop Kantarjian; Pamela Allen; Gabriela Rondon; Partow Kebriaei; Susan O'Brien; Aziza Kedir; Mustefa Said; Jonathan D Grant; Deborah A Thomas; Paul W Gidley; Isidora Arzu; Chelsea Pinnix; Valerie Reed; Bouthaina S Dabaja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

10.  Acute myeloid leucaemia presenting as a rapidly progressive polyradiculoneuropathy.

Authors:  Claire L Hirst; Mark Willis; Hussain Hussain; Rob Powell
Journal:  BMJ Case Rep       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.